PD-1 inhibitor-augmented HAIC-TKI therapy in hepatocellular carcinoma with portal vein tumor thrombosis: real-world survival benefits, safety, and subgroup-specific efficacy

PD-1 inhibitor-augmented HAIC-TKI therapy in hepatocellular carcinoma with portal vein tumor thrombosis: real-world survival benefits, safety, and subgroup-specific efficacy

BackgroundPD-1/PD-L1 inhibitors have shown efficacy in improving the prognosis of patients with hepatocellular carcinoma (HCC) accompanied by portal vein tumor thrombosis (PVTT) in pivotal clinical trials including the landmark IMbrave150 study. However, not all the patients benefit from the PD-1/PD...

Full description

Saved in:
Bibliographic Details
Main Authors: Fei Cao, Chunyong Wen, Yujia Wang, Hongtong Tan, Shaohuan Hao, Jinbin Chen, Shuanggang Chen, Lujun Shen, Lin Xie, Han Qi, Tao Huang, Yaojun Zhang, Zilin Huang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Immunology
Subjects:
PD-1 inhibitor
hepatic arterial infusion chemotherapy
tyrosine kinase inhibitors (TKIs)
portal vein tumor thrombosis
hepatocellular carcinoma
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1602031/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1602031/full

Similar Items